Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder

All NewsSeptember 16, 2025

Adial Pharmaceuticals received FDA backing for its Phase 3 AD04 trial, including endpoints and strategies for targeted populations in Alcohol Use Disorder treatment.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent